YSYulia Shevtsova

Yulia Shevtsova

*This is an algorithmically generated author record based on publicly available information.

Yulia Shevtsova has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Depth filtration coupled with proteomics identifies colorectalcancer-specific extracellular vesicle protein corona as potential biomarker

    by Ekaterina Moiseeva, Anna Bugrova, Yulia Shevtsova, Elena V. Svirshchevskaya, Alexander Yakovlev, Elizaveta Polyanskaya, Mikhail Yu. Fedyanin, Mikhail Ivanov, Denis Silachev, Alexey Kononikhin, et al.

    The clinical translation of extracellular vesicle (EV)-based diagnostics remains hindered by the lack of rapid, non-degradative, and scalable isolation methods compatible with robust biomarker discovery. In this study we use express asymmetric depth filtration method and compare it directly with ultrafiltration coupled with size-exclusion chromatography for EV isolation from two colorectal cancer cell lines, HCT116 and HT29. The two methods yield distinct EV subpopulations, with depth filtration providing faster processing and good purity suitable for proteomics. Using depth filtration, we performed comparative proteomic profiling of EVs from CRC, ovarian (SKOV3), and breast (SKBR3) cancer cell lines to identify candidate CRC-associated protein markers. To assess clinical relevance, we then isolated EVs from the blood plasma of healthy donors and stage III CRC patients using depth filtration and analyzed their proteomes. Six proteins were overexpressed in both CRC cell line EVs and plasma-derived CRC EVs relative to the other cancer types and healthy controls. Three of these six proteins – fibrinogen gamma, fibronectin, and vitronectin, each of which is a surface EVs protein – were validated by ELISA in an independent cohort (12 CRC patients, 8 healthy donors), confirming their elevated expression on CRC patient plasma EVs. Notably, EV-associated protein levels showed better stage discrimination (stage I–II vs. III–IV) than total plasma protein levels. These findings demonstrate that depth filtration enables rapid, clinically compatible EV isolation and that comparative proteomics of cell line and plasma EVs can identify robust, stage-sensitive CRC biomarkers for liquid biopsy development.